The invention relates to novel compounds of the general formula (I), ##STR1## wherein R means hydrogen or a straight or branched chain C.sub.1-6 alkoxy group; R.sup.1 stands for hydrogen or a straight or branched chain C.sub.1-6 alkyl group; R.sup.2 represents hydrogen or a straight or branched chain C.sub.1-6 alkyl group; R.sup.3 means hydrogen, a straight or branched chain C.sub.1-6 alkyl group optionally substituted by one or two hydroxyl and/or one or two straight or branched chain C.sub.1-4 alkoxy group(s); or a C.sub.4-7 cycloalkyl group; R.sup.4 stands for hydrogen or a straight or branched chain C.sub.1-6 alkyl group optionally substituted by one or two hydroxyl and/or one or two straight or branched chain C.sub.1-4 alkoxy group(s); or a C.sub.4-7 cycloalkyl group; or R.sup.3 and R.sup.4 together with the nitrogen atom, to which they are attached form a 4 to 8-membered cyclic group of formula ##STR2## optionally substituted by one or two straight or branched chain C.sub.1-4 alkoxy and/or one or two straight or branched chain C.sub.1-4 alkyl group(s), where optionally an oxygen or sulfur atom or an N-R.sup.5 group may be substituted for a ring carbon atom, where R.sup.5 means hydrogen or a straight or branched chain C.sub.1-6 aliphatic alkyl group, the 4- to 8-membered cycle optionally being condensed with a benzene ring; R.sup.6 stands for hydrogen or a C.sub.1-10 acyl group and the salts and hydrates thereof as well as pharmaceutical compositions containing these compounds. The compounds of the invention antagonize the effects of constrictive mediators, e.g. histamine, acetylcholine or serotonin; they show an antiallergic action and possess an antiinflammatory effect. Thus, these compounds can therapeutically be used as bronchodilators as well as antiallergic or antiinflammatory drugs, particularly in the treatment of bronchial asthma.

Description

41 parts

›FIELD OF THE INVENTION

This invention relates to novel compounds of the formula (I), ##STR3## wherein R means hydrogen or a straight or branched chain C 1-6 alkoxy group;

R 1 stands for hydrogen or a straight or branched chain C 1-6 alkyl group;

R 2 represents hydrogen or a straight or branched chain C 1-6 alkyl group;

R 3 means hydrogen; a straight or branched chain C 1-6 alkyl group optionally substituted by one or two hydroxyl and/or one or two straight or branched chain C 1-4 alkoxy groups; or a C 4-7 cycloalkyl group;

R 4 stands for hydrogen or a straight or branched chain C 1-6 alkyl group optionally substituted by one or two hydroxyl and/or one or two straight or branched chain C 1-4 alkoxy groups; or a C 4-7 cycloalkyl group; or

R 3 and R 4 together with the nitrogen atom, to which they are attached form a 4 to 8-membered cyclic group of formula ##STR4## optionally substituted by one or two straight or branched chain C 1-4 alkoxy and/or one or two straight or branched chain C 1-4 alkyl group(s), where optionally an oxygen or sulfur atom or an N-R 5 group may be substituted for a ring carbon atom, where R 5 means hydrogen or a straight or branched chain C 1-6 aliphatic alkyl group, the 4- to 8-membered cycle optionally being condensed with a benzene ring;

R 6 stands for hydrogen or a C 1-10 acyl group and their salts. The invention also relates to the pharmaceutical compositions containing these compounds.

The invention relates also to a process for the preparation of the above new compounds and compositions.

The compounds of formula (I) are unknown in the literature.

R as alkoxy means inter alia a methoxy, ethoxy, propyloxy, isopropyloxy, butoxy, pentoxy or hexyloxy group.

R 1 and R 2 may stand e.g. for methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, secondary butyl, pentyl or isopentyl group.

R 3 and R 4 may mean inter alia the groups defined for R 1 or R 2 as well as 2-hydroxyethyl or cyclohexyl group. ##STR5## may stand inter alia for a piperidinyl, piperazinyl, 4-methyl-1-piperazinyl, morpholinyl, hexamethylenimino or 1-pyrrolidinyl group.

R 6 may represent e.g. an acetyl or benzoyl group.

›BACKGROUND OF THE INVENTION

The frequency of occurrence of allergic diseases, particularly bronchial asthma is continuously increasing. Social-economical and environmental conditions, enhancement of effectivity of the diagnostics and the lack of an adequate, really healing therapy provide background of this increase. Despite for or partially even due to the elevated drug consumption, the mortality ratio also shows a rising tendency.

Asthma is characterized by an increased sensitivity of the respiratory smooth muscles to the most various stimuli, which leads to a reversible constriction or obstruction of the airways. Chronic asthma eventually results in an irreversible airway obstruction.

Here, an uncontrolled inflammatory process of the respiratory tract appears to be involved. A therapy, which is based only on a bronchodilatation without affecting and even masking the above process represents a merely symptomatic treatment which is essentially harmful and likely contributes to the increase in the mortality.

In opposition to this, an antiinflammatory therapy suppresses the inflammation and at least slows down the harmful background process as well as diminishes the frequency of the demand on a simultaneously used bronchodilatory treatment.

In the cases of drugs being available at present, a further problem appears in the adverse effects decreasing to a high degree their usefulness.

Thus, a most advantageous therapy could be ensured by a drug which is effective against mediator substances causing a spasm of the respiratory smooth muscles and simultaneously possessing antiinflammatory or antiallergic effect without any adverse side effect.

Due to the pathologic nature of bronchial asthma, the effects against the possibly highest number of mediator substances, being constrictive or even inflammatory in character, is very important since the actions of many kinds of endogeneous substances are simultaneously exerted. It would be arbitrary to suppose an outstanding role of any component. Thus, the simultaneous presence of each of the effects defined above is important for these drugs to be developed for the treatment of bronchial asthma.

›DESCRIPTION OF THE INVENTION · 1 of 2

Now, it has been found during the pharmacological study on the compounds of formula (I) that these substances antagonize the effects of constrictor-type mediators (e.g. histamine, acetylcholine, serotonin), show an antiallergic action and possess an antiinflammatory effect. Thus, the compounds of formula (I) have a bronchodilator-type effect (similarly to the β 2 antagonists or theophylline) as well as an antiallergic or antiinflammatory action (similarly to the glucocorticoids, cromolyn or nedocromyl).

Therefore, the compounds of general formula (I) extensively satisfy the therapeutic demands discussed above since they associate the bronchodilatory, antiallergic, and antiinflammatory activities with an advantageous lack of toxicity and without harmful side effects (without adverse effects).

The invention relates also to a process for the preparation of the new compounds of formula (I), wherein

R means hydrogen or a straight or branched chain C 1-6 alkoxy group;

R 1 stands for hydrogen or a straight or branched chain C 1-6 alkyl group;

R 2 represents hydrogen or a straight or branched chain C 1-6 alkyl group;

R 3 means hydrogen; a straight or branched chain C 1-6 alkyl group optionally substituted by one or two hydroxyl and/or one or two straight or branched chain C 1-4 alkoxy groups or a C 4-7 cycloalkyl group;

R 3 and R 4 together with the nitrogen atom, to which they are attached form a 4 to 8-membered cyclic group of formula ##STR6## optionally substituted by one or two straight or branched chain C 1-4 alkoxy and/or one or two straight or branched chain C 1-4 alkyl groups, where optionally an oxygen or sulfur atom or an N-R 5 group may be substituted for a ring carbon atom, where R 5 means hydrogen or a straight or branched chain C 1-6 aliphatic alkyl group, the 4- to 8-membered cycle optionally being condensed with a benzene ring;

R 6 stands for hydrogen or a C 1-10 acyl group and their salts, which comprises hydrolyzing a compound of the formula (II), ##STR7## wherein R, R 1 and R 2 are as defined above and X means a halide ion, then reacting the obtained derivative of formula (III) ##STR8## wherein R, R 1 and R 2 are as defined above and Me means a metal atom

a) with a racemic or optically active amino alcohol derivative of formula (IV), ##STR9## wherein the ##STR10## group is as defined above and Y stands for halogen or arylsulfonyl group, or

b) with an epoxypropylamine derivative of the formula (V) ##STR11## wherein the ##STR12## group is defined above, then, if desired, acylating the thus obtained active compounds of formula (I), wherein R, R 1 , R 2 , R 3 , R 4 and R 5 are as defined above and R 6 stands for hydrogen, by known methods to obtain compounds of the formula (I), wherein R 6 is as defined above, except hydrogen; or resolving the racemic compounds of formula (I) by known methods; or converting the racemic or optically active compounds of formula (I) to their salts; or liberating the free compounds of formula (I) from their salts.

According to the process of the invention the compounds of formula (II) can be hydrolyzed in aqueous organic solvents, preferably in aqueous aliphatic alcohols by adding a base, suitably an alkaline metal hydroxide. According to a preferred embodiment of this reaction the alkaline metal hydroxide or the aqueous solution thereof is added to the reaction mixture, then the reaction is carried out at the boiling point of the solvent mixture. However, the hydrolysis may be accomplished also under stirring at room temperature since the compounds of formula (II) are hydrolyzed also at lower temperatures.

Although the hydrolysis of compounds of the formula (II) starts even after adding 1 molar equivalent of alkali, this process is rather low, therefore it is suitable to use the alkali in excess. When the compounds of formula (III) are reacted with compounds of the formula (IV) or their salts or with the salts of compounds of the formula (V), the amount of alkali needed to liberate the base from the latter salts may already be added to the reaction mixture during the hydrolysis of the compounds of formula (II). On reacting the thiols of formula (III) with the salts of the compounds of formula (IV) it is suitable to carry out the reaction in the presence of 2 to 6 moles of alkali. The amount of the base used is proportionally diminished when the compounds of formula (IV) or (V) are added in their base form to the reaction mixture.

It is suitable to react the thiols of formula (III), present in solution as their salts after hydrolysis, without isolation with the compounds of formula (IV) or (V). The compounds of formula (IV) or (V) may be added as their solid salts to the reaction mixture. However, alternatively, after dissolving the salts of the compounds of formula (IV) or (V) in water or in a mixture of water with a water-miscible organic solvent, preferably an alcohol, their solutions may be added dropwise to the reaction mixture. The addition may be carried out while refluxing the reaction mixture but a lower temperature may also be used. The substances of formula (IV) or (V) can also be employed in their free base form; the addition may be achieved by using or without a solvent.

After adding the compounds of formula (IV) or (V) the reaction mixture is further boiled under a reflux condenser or stirred at a lower temperature, if desired, even under cooling. The compounds of formula (I) formed in the reaction remain in solution in their free base form. After termination of the reaction the products of formula (I) are isolated by using commonly known working up methods. The organic solvent is preferably evaporated under reduced pressure, whereby the product of formula (I) is separated in an oily or crystalline form from the remaining aqueous medium. Any crystalline base of the formula (I) is separated from the mother liquor by filtration whereas the oily crude products are extracted from the aqueous phase. The extraction may be carried out by using water-immiscible solvents, e.g. ethers, hydrocarbons, halogenated hydrocarbons and the like commonly employed for this purpose. After extraction the solutions are dried and the solvent is evaporated under reduced pressure. The evaporation residue is an oily product which becomes crystalline in several cases while standing or by rubbing as both crystalline and oily substances may occur among the bases of formula (I).

›DESCRIPTION OF THE INVENTION · 2 of 2

The crude products of formula (I) can be purified as crude bases or alternatively, the crude bases may be converted to their salts with mineral or organic acids, and, if desired, the salts obtained may be subjected to a further purification. Methods commonly used in the synthetic organic chemistry such as recrystallization, cromatographical methods and the like can be employed for the purification. Preferred and pharmacologically acceptable salts can be formed by using e.g. hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid or phosphoric acid as inorganic acids; or citric acid, acetic acid, formic acid, succinic acid, lactic acid, malonic acid, maleic acid, propionic acid, fumaric acid and ascorbic acid as organic acids. Other organic or inorganic acids are also suitable.

A possibility of separation of optically active antipodes comprises forming salts of the compounds of formula (I) with optically active acids and then crystallizing the salts obtained. This method may be accomplished under the usual conditions of resolution by using commonly employed optically active acids such as d-tartaric acid and derivatives thereof, d-camphorsulfonic acid, d-camphoric acid and the like. The salt formation may be carrried out in organic solvents or in a mixture thereof. The precipitating crystalline salts are purified by recrystallization from organic solvents, preferably from alcohols (e.g. ethanol, isopropanol). After resolution the optically active bases are liberated by adding an alkali. The salts of the antipodes formed with mineral acids can be obtained by adding mineral acids without liberating the bases; alternatively, these salts may be formed by reacting the optically active bases with mineral acids.

Compounds of the formula (I) containing a C 1-10 acyl group as R 6 are prepared by the acylation of compounds of the formula (I), wherein R 6 is hydrogen. The acylation may be performed by using acyl halides or anhydrides, preferably in the presence of organic or inorganic bases in a manner known per se. This reaction may be carried out in a solvent or by using an excess of the acylating agent (e.g. acetic anhydride) as solvent. All solvents being inert to the acylating agents (e.g. hydrocarbons, halohydrocarbons, pyridine) are useful for this purpose. The products are isolated by the usual methods, e.g. evaporation and recrystallization.

The starting substances of formula (II) and the process for their preparation are known from the German patent specification No. 2,426,267.

The compounds of formula (IV) are known and can be prepared according to J. Org. Chem. 25, 1424 (1960). The compounds of formula (V) are also known and are prepared as described in J. Am. Chem. Soc. 80, 1257 (1958).

The pharmacological effects of the compounds according to the invention were investigated by using the methods described hereinafter.

›SPECIFIC EXAMPLES · 1 of 2

I Study on the Effects Against Spasmogenic Mediators

[modified method of J. C. Castillo et al.: Exp. Ther. 90, 104 (1947)]

The investigation on isolated organs were carried out as follows.

OHF Lt/R9 guinea pigs of both sexes weighing 300 to 400 g each were anaesthetized by pentobarbital. Their trachea was removed and sectioned in the opposite side to the site of smooth muscle in longitudinal direction. Subsequently, a strip-like preparation was obtained by serrately cutting.

The organ was suspended in an organ bath containing 35 ml of Krebs solution at 37° C. bubbled through by carbogen gas (consisting of 95% of oxygen and 5% of carbon dioxide).

A rest load of 0.5 g was used. Several washings were carried out during the incubation period of 30 minutes.

The change in the tension of the tracheal smooth muscle was followed by using an isometric Grass FT-03 type tensiometer sensor device. A washing was made following the cumulative dose series of the given mediator (e.g. histamine). After reaching the base line, by 15 minutes after administration of the given concentration of the inhibitory (antiasthmatic) substance to be tested, the next cumulative dose series of the mediator was administered. In the case of an inhibitory action, the strength of effect, following the second dose series of the mediator, was increased in comparison to that of the first (control) series.

For characterization of strength of the competitive antagonistic effect the pA 2 value was determined according to the method of Schield [Br. J. Pharmacol. 4, 277 (1949)]. A pd' 2 value was calculated [J. M. Van Rossum: Arch. Int. Pharmacodyn 143, 317 (1963)] to characterize the noncompatitive antagonistic effectivity. The higher the pA 2 or pd' 2 value, respectively were, the higher was the antagonistic effect.

Theophylline was used as reference drug having the following values:

pd' 2 value against histamine: 5.80

pd' 2 value against acetylcholine: 6.43

pd' 2 value against serotonin: 6.49

The results obtained in the above test by the compounds of formula (I) of the invention are summarized in Table I.

______________________________________

Inhibition of the histamine-induced

Compound of constriction of isolated tracheal

the Example No.

smooth muscle of guinea pig pd'.sub.2

______________________________________

1 5.04

2 4.91

3 4.57

4 4.30

5 4.34

6 6.69

7 4.76

8 4.87

9 4.38

10 3.98

11 4.45

12 4.81

13 4.90

14 4.58

15 4.46

16 4.49

17 5.74

18 6.91

19 4.01

21 5.54

22 5.14

23 4.76

24 5.93

25 6.38

26 5.06

27 6.27

28 6.36

theophylline 5.80

______________________________________

II. Study of the Antiallergic Effect

1) The effect influencing the active local anaphylactic reaction was measured according to the method of M. Koltay [Arch. Allergy App. Immun. 71, 181 (1983)].

Female OFA rats weighing 160 to 180 g each were sensitized by bovine serum albumin (BSA) adsorbed to 50 μg of Al(OH) 3 gel together with the simultaneous administration of Bordatella pertussis vaccine.

The anaphylactic reaction was elicited by injecting 100 μg of BSA into the right hind paw plant in the 14th day.

The measurements were carried out before and 30 minutes after eliciting the reaction. The animals were orally treated with the compound to be tested 1 hour before the injection of BSA. The results were expressed as percentage inhibition compared to the control group (average %±S.E.M.).

2) The acute antiinflmmatory effect was determined by using the carrageenin-induced rat paw edema test [C. A. Winker et al.: Proc. Soc. Exp. Med. 111, 544 (1962)].

Female CFY rats weighing 100 to 120 g each were used after starvation for 24 hours.

The inflammation was induced by injecting 0.1 ml of 1% carrageenin solution into the right hind paw plant.

The severity of inflammation was determined by using an Ugo-Basile type plethysmometer. The measurement was carried out before and 1.5, 3 and 4.5 hours after induction of the inflammation.

The animals were orally treated with the substance to be tested 1 hour before administration of carrageenin. The effect was expressed as percentage inhibition related to the control group.

3) Dextran-induced rat paw edema test

The method of S. Gourvaisier and R. Ducrot [Arch. Int. Pharmacodyn. Ther. 102, 33 (1955)] was employed.

The method described for the carrageenin edema test was followed, except that the measurements were carried out 30, 60, 90, 120 and 180 minutes after induction of the inflammation.

For the use as medicaments, the compounds of formula (I) and their salts are formulated to pharmaceutical compositions such as tablet, dragee, suppository, capsule, solution, powder mixture, injectable or inhalation compositions after adding various additives by methods commonly used in the pharmaceutical industry. Being in readily soluble in aqueous media, the salts of compounds of the formula (I) are convenient to utilize for the preparation of solutions which can therapeutically be used in both injectable and inhalable compositions.

The reference substances listed hereinafter together with their pharmacological values were utilized in the investigations discussed hereinabove.

______________________________________

1. Inhibition of the spasmogenic mediator-induced constric-

tion of the isolated tracheal smooth muscle of the guinea pig

Histamine Serotonin

Acetylcholine

______________________________________

pd'.sub.2 of theophylline

5.80 6.16 6.43

______________________________________

2. Effect influencing the active local anaphylactic reaction

on rat

Oral dose Protective effect %

Compound mg/kg in the 30th minute

______________________________________

Naproxen 30 2.2

BW 755C 50 52.9

Dexamethasone

0.5 45.5

______________________________________

3. Carrageenin-induced rat paw edema

Protective effect %

Oral dose

1.5 3 4.5

Compound mg/kg hours

______________________________________

Naproxen 20 33.2 44.3 40.4

______________________________________

4. Dextran-induced rat paw edema test

Protective effect %

Oral dose

30 60 90 120 180

Compound mg/kg minutes

______________________________________

Naproxen 20 16.9 20.1 18.9 23.3 21.6

BW-755C 50 15.4 12.3 17.2 7.9 11.3

›SPECIFIC EXAMPLES · 2 of 2

dexamethasone

0.5 42.7 36.8 51.1 52.1 45.5

______________________________________

The invention is further illustrated in detail by the following non-limiting Examples.

›Examples21

›EXAMPLE 1

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-diethylamino-2-hydroxypropyl)-mercaptoacetonitrile hydrochloride

After dissolving 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-methyl]isothiuronium bromide (prepared as described in our earlier German patent specification No. 2,426,267) in the mixture of 80 ml of ethanol and 20 ml of water by heating, 16.0 ml of 10% sodium hydroxide solution are added and the reaction mixture is refluxed for 90 minutes, then 1.7 g of 1-chloro-3-diethylamino-2-propanol dissolved in 10 ml of methanol (prepared by reacting diethylamine with epichlorohydrin in methanol according to J. Org. Chem. 25, 1424 (1960)) are added dropwise to the mixture. After refluxing the reaction mixture for 6 hours and then evaporating the organic solvent under reduced pressure, concentrated hydrochloric acid is added dropwise to the remaining aqueous-oily residue until reaching a pH value of 5 to 6. The solution is clarified by activated charcoal, filtered and the filtrate is alkalized by adding 10% sodium hydroxide solution. A yellow oil precipitates which becomes solid by rubbing. After filtration and drying, the product is dissolved in 20 ml of isopropanol and acidified by adding hydrogen chloride in abs. ethanol solution to obtain 1.8 g of the named compound, m.p.: 179° C.

Analysis for C 20 H 30 ClN 3 O 3 S (molecular weight 427.99) calculated: N 9.82; Cl 8.28; S 7.49%; found: N 9.91; Cl 8.40; S 7.50%.

›EXAMPLE 2

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-diethylamino-2-hydroxypropyl)-mercaptoacetonitrile hydrochloride

The process described in Example 1 is followed, except that 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-methyl]isothiuronium bromide and 1-chloro-3-diethylamino-2-propanol are used as reactants to give the named compound in a yield of 2.1 g, m.p.: 149° C.

Analysis for C 22 H 34 ClN 3 O 3 S (molecular weight 456.04) calculated: N 9.22; Cl 7.77; S 7.03%; found: N 9.08; Cl 7.93; S 7.31%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-22.9 -20.6 -11.3

protective effect

______________________________________

Inhibition of development of the dextran-induced rat paw edema:

______________________________________

50 mg/kg (p.o.)

30 60 90 120 180 minutes

Percentage of

-24 -21 -25 -23 -17

inhibition

______________________________________

›EXAMPLE 3

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinolinylidene)-2-[3-(N-methyl-N-2-hydroxyethyl)-amino-2-hydroxypropyl]-mercapto-acetonitrile hydrochloride

The process described in Example 1 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]-isothiuronium bromide and 1-chloro-3-(N-methyl-N-2-hydroxyethyl)-amino-2-propanol as starting substances to obtain the named compound in a yield of 2.6 mg, m.p.: 136° C. (from abs. ethanol).

Analysis for C 19 H 28 ClN 3 O 4 S (molecular weight 429.96) C H N Cl S calculated: 53.07 6.56 9.77 8.25 7.46%; found: 52.82 6.82 9.40 8.13 7.50%.

›EXAMPLE 4

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[3-(N,N-bis-2-hydroxyethyl)-amino-2-hydroxypropyl]-mercapto-acetonitrile hydrochloride dihydrate

The process described in Example 1 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]-isothiuronium bromide and 1-chloro-3-(N,N-bis-2-hydroxyethyl)-amino-2-propanol as starting substances to obtain the title compound in a yield of 2.3 g, m.p.: 135° C. (from 96% etanol).

Analysis for C 20 H 34 ClN 3 O 7 S (molecular weight 496.02) C H N Cl S calculated: 48.43 6.91 8.47 7.15 6.46%; found: 48.66 6.77 8.25 7.45 6.31%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-25.0 -26.0 -24.0

protective effect

______________________________________

›EXAMPLE 5

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[3-(N,N-bis-2-hydroxyethyl)-amino-2-hydroxypropyl]mercapto-acetonitrile hydrochloride

The process described in Example 1 is followed by using 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]-isothiuronium bromide and 1-chloro-3-(N,N-bis-2-hydroxyethyl)-amino-2-propanol as starting substances to obtain the named compound in a yield of 3.1 g, m.p.: 165° C. (from abs. ethanol).

Analysis for C 22 H 34 ClN 3 O 5 S (molecular weight 488.04) C H N Cl S calculated: 54.14 7.02 8.61 7.27 6.57%; found: 54.14 7.00 8.61 7.31 6.30%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-21.0 -16.5 -10.0

protective effect

______________________________________

›EXAMPLE 6

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(2-hydroxy-3-isopropylaminopropyl)mercaptoacetonitrile hydrochloride hemihydrate

The process described in Example 1 is followed, by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]-isothiuronium bromide and 1-chloro-3-isopropylamino-2-propanol as starting substances to give the named compound in a yield of 2.6 g, m.p.: 176° C. (from isopropanol).

Analysis for Cl 19 H 28 ClN 3 O 3 S.0.5H 2 O (molecular weight 422.97) C H N Cl S calculated: 53.95 6.91 9.94 8.38 7.58%; found: 53.60 6.69 10.24 8.47 7.60%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

0 -17.0 0

protective effect

______________________________________

›EXAMPLE 7

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(2-hydroxy-3-isopropylaminopropyl)mercaptoacetonitrile hydrochloride

The process described in Example 1 is followed, by using 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydroisoquinolinylidene)methyl]-isothiuronium bromide and 1-chloro-3-isopropylamino-2-propanol as starting substances to obtain the title compound in a yield of 2.8 g, m.p.: 185° C. (from isopropanol).

Analysis for C 21 H 32 ClN 3 O 3 S (molecular weight 442.01) C H N Cl S calculated: 57.06 7.30 9.51 8.02 7.25%; found: 56.78 7.35 9.70 8.31 7.05%.

›EXAMPLE 8

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-tert-butylamino-2-hydroxypropyl)mercaptoacetonitrile hydrochloride

After adding 80 ml of ethanol and 20 ml of water to 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide, the mixture is heated until dissolution of the solid material (1 to 2 minutes). After adding 16.0 ml of 10% sodium hydroxide solution, the mixture is refluxed for 90 minutes. Subsequently, 2.02 g of 3-tert-butylamino-1-chloro-2-propanol hydrochloride (prepared by reacting tert-butylamine with epichlorohydrin in methanol as described in the literature cited above, then precipitating the salt from isopropanol solution of the crude base, by adding ethanolic hydrogen chloride solution; m.p. of the hydrochloride: 160° C.) are portionwise added to the reaction mixture which is then refluxed for 5 hours, thereafter ethanol is evaporated under reduced pressure. The residue is the yellow oily crude base, which becomes crystalline while standing, m.p.: 112° C. The crude base is obtained in a yield of 3.6 g.

By adding ethanolic hydrogen chloride solution to an isopropanol solution of the crude base the named hydrochloride is obtained, m.p.: 177° C.

Analysis for C 20 H 30 ClN 3 O 3 S (molecular weight 427.99) C H N Cl S calculated: 56.12 7.07 9.82 8.28 7.49%; found: 56.40 6.87 9.82 8.38 7.72%.

›EXAMPLE 9

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-tert-butylamino-2-hydroxypropyl)mercaptoacetonitrile hydrochloride hemihydrate

The process described in Example 8 is followed by using 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 3-tert-butylamino-1-chloro-2-propanol hydrochloride as starting substances to obtain the named compound in a yield of 2.4 g, m.p.: 160° C. (from isopropanol).

Analysis for C 22 H 34 ClN 3 O 3 S.0,5H 2 O (molecular weight 465.05) C H N Cl S calculated: 56.82 7.59 9.04 7.62 6.90%; found: 56.70 7.76 9.00 7.95 6.82%.

›EXAMPLE 10

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-cyclohexylamino-2-hydroxypropyl)mercaptoacetonitrile hydrochloride

The process described in Example 1 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-methyl]isothiuronium bromide and 1-chloro-3-cyclohexylamino-2-propanol as starting substances to obtain the named product in a yield of 2.7 g, m.p.: 190° C. (from isopropanol).

Analysis for C 22 H 32 ClN 3 O 3 S (molecular weight 454.02) C H N Cl S Calculated: 58.20 7.10 9.26 7.81 7.06%; found: 58.00 7.40 9.02 7.81 6.86%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-14.8 -13.0 -7.2

protective effect

______________________________________

Inhibition of development of the dextran-induced rat paw edema:

______________________________________

50 mg/kg (p.o.)

30 60 90 120 180 minutes

Percentage of

-25 -24 -25 -27 -50

inhibition

______________________________________

›EXAMPLE 11

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-cyclohexylamino-2-hydroxypropyl)mercaptoacetonitrile hydrochloride

The process described in Example 1 is followed by using 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene) methyl]isothiuronium bromide and 1-chloro-3-cyclohexylamino-2-propanol as starting substances to obtain the title product in a yield of 2.6 g, m.p.: 182° C. (from isopropanol).

Analysis for C 24 H 36 ClN 3 O 3 S (molecular weight 482.08) C H N Cl S calculated: 59.79 7.53 8.72 7.36 6.65%; found: 60.02 7.50 8.65 7.16 6.45%.

›EXAMPLE 12

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-pyrrolidinyl)propyl]mercaptoacetonitrile hydrochloride hemihydrate

The process described in Example 1 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(1-pyrrolidinyl)-2propanol as starting substances to give 2.1 g of the named product, m.p.: 194° C. (from ethanol).

Analysis for C 20 H 28 ClN 3 O3S.0,5H 2 O (molecular weight 434.98) C H N Cl S calculated: 55.22 6.72 9.66 8.15 7.37%; found: 55.18 7.03 9.90 8.15 7.55%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-27.2 -18.9 -17.6

protective effect

______________________________________

Inhibition of development of the dextran-induced rat paw edema:

______________________________________

50 mg/kg

30 60 90 120 180 minutes

(p.o.)

Percentage

-20.2 -15.6 -14.7 -14.6 -12.6

of inhibi-

tion

______________________________________

›EXAMPLE 13

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-pyrrolidinyl)propyl]mercaptoacetonitrile hydrochloride

The process described in Example 1 is followed by using

4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(1-pyrrolidinyl)-2-propanol to obtain the named product in a yield of 2.6 g, m.p.: 195° C. (from ethanol).

Analysis for C 22 H 32 ClN 3 O 3 S (molecular weight 454.02) C H N Cl S calculated: 58.20 7.10 9.26 7.81 7.06%; found: 57.92 7.30 9.20 7.48 6.82%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-31.8 -21.8 -9.05

protective effect

______________________________________

›EXAMPLE 14

Preparation of 2-(1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-piperidinyl)propyl]mercaptoacetonitrile

The process described in Example 8 is followed by using 3.25 g of S-[α-cyano-α-(1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(1-piperidinyl)-2-propanol to give the named product in a yield of 2.1 g, m.p.: 103° C. (from isopropanol).

Analysis for C 19 H 25 N 3 OS (molecular weight 343.48) C H N S Calculated: 66.43 7.34 12.23 9.34%; found: 66.17 7.14 12.50 9.24%.

The hydrochloride of the named product is obtained by adding abs. ethanolic hydrogen chloride solution to the base dissolved in abs. ethanol, m.p.: 187° C.

Inhibition of the active local anaphylactic reaction:

The percentage of inhibition achieved by an oral dose of 50 mg/kg of body weight is -44.1% in the 30th minute after induction of the reaction.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-20.9 -20.0 -20.0

protective effect

______________________________________

›EXAMPLE 15

Preparation of 2-(6,7-dimethoxy-1,2,3,4,-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-piperidinyl)propil]mercaptoacetonitrile hydrochloride

After dissolving 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide in a mixture of 80 ml of ethanol with 20 ml of water under heating, 16 ml of 10% sodium hydroxide solution are added and the reaction mixture is refluxed for 2 hours, then cooled to room temperature and 2.2 g of 1-chloro-3-(1-piperidinyl)-2-propanol hydrochloride are added to the reaction mixture while stirring. The mixture is stirred at room temperature for 2 days and then worked up as described in Example 1. In this way 2.7 g of the named hydrochloride are obtained, m.p.: 210° C. (from ethanol).

Analysis for C 21 H 30 N 3 O 3 S (molecular weight 440.00) C H N S calculated: 57.32 6.87 9.55 7.29%; found: 56.99 7.01 9.32 7.43%.

›EXAMPLE 16

Preparation of 2-(1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile hydrochloride hemihydrate

The process described in Example 15 is followed by using 3.25 g of S-[α-cyano-α-(1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(4-morpholinyl)-2-propanol hydrochloride as starting substances to obtain 2.7 g of the title product, m.p.: 195° C. (from ethanol).

Analysis for C 18 H 24 ClN 3 O 2 S.0.5H 2 O (molecular weight 390.93) C H N S calculated: 55.30 6.44 10.75 8.20%; found: 55.10 6.30 10.50 8.37%.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-29.3 -22.2 -20.0

protective effect

______________________________________

›EXAMPLE 17

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile hydrochloride

The process described in Example 15 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(4-morpholinyl)-2-propanol hydrochloride as starting materials to obtain the named compound in a yield of 3.3 g, m.p.: 210° C. (from ethanol).

Analysis for C 20 H 28 ClN 3 O 4 S (molecular weight 441.97) C H N Cl S calculated: 54.35 6.39 9.51 8.02 7.26; found: 54.42 6.52 9.63 8.00 7.54.

Inhibition of the active local anaphylactic reaction:

The percentage of inhibition achieved by an oral dose of 50 mg/kg is -53.4% in the 30th minute following induction of the reaction.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-4.2 0 0

protective effect

______________________________________

Inhibition of development of the dextran-induced rat paw edema:

______________________________________

50 mg/kg (p.o.)

30 60 90 120 180 minutes

Percentage of

27.5 32.5 32.1 32.4 20.3

inhibition

______________________________________

›EXAMPLE 18

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile

After adding 80 ml of methanol and 20 ml of water to 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide, the reaction mixture is heated until complete dissolution (1 to 2 minutes). After adding 11.0 ml of 10% sodium hydroxide solution the mixture is refluxed for 90 minutes. After addition of 2.2 g of 1-chloro-3-(4-morpholinyl)-2-propanol hydrochloride, the reaction mixture is refluxed for 5 hours. Then, methanol is evaporated and the residue is cooled down, whereby the crude base crystallizes out to give the named product in a yield of 3.2 g, m.p.: 97° C. (from abs. ethanol).

Analysis for C 22 H 31 N 3 O 4 S (molecular weight 433.56) C H N S calculated: 60.94 7.21 9.69 7.40%; found: 60.72 7.40 9.5 7.17%.

The hydrochloride of the above base is precipitated by adding an ethanolic solution of hydrogen chloride to an abs. ethanolic solution of the base, m.p.: 203° C. (from ethanol).

______________________________________

LD.sub.50 i.v.

91.37 mg/kg on male rat

132.98 mg/kg on female rat

165.76 mg/kg on male mouse

150.00 mg/kg on female mouse

LD.sub.50 p.o.

1204.59 mg/kg on male mouse

1034.65 mg/kg on female mouse

______________________________________

Inhibition of the active topic anaphylactic reaction

The percentage of inhibition achieved by an oral dose of 50 mg/kg is -31% in the 30th minute following the induction of reaction.

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-35.8 -29.3 -28.4

protective effect

______________________________________

Inhibition of development of the dextran-induced rat paw edema:

______________________________________

50 mg/kg (p.o.)

30 60 90 120 180 minutes

Percentage of

29.8 38.7 30.4 26.3 28.4

inhibition

______________________________________

›EXAMPLE 19

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-hexamethylenimino-2-hydroxypropyl)mercaptoacetonitrile

The process described in Example 1 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-hexamethylenimino-2-propanol as starting materials to obtain 1.7 g of the named base as a yellow oil.

The hydrochloride of the above base is precipitated from ethanolic solution. The hydrochloride crystallizes with 1 mole of crystal ethanol and half mole of crystal water, m.p.: 110° to 112° C. (from ethanol).

______________________________________

Analysis for C.sub.22 H.sub.31 N.sub.3 O.sub.3 S.HCl.C.sub.2 H.sub.5

OH.0.5H.sub.2 O

(molecular weight 509.10)

C H N Cl S

______________________________________

calculated:

56.62 7.72 8.25 6.96 6.30%;

found: 56.66 8.05 8.20 6.70 6.65%.

______________________________________

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-29.0 -24.2 -19.5

protective effect

______________________________________

Inhibition of development of the dextran-induced rat paw edema:

______________________________________

50 mg/kg

30 60 90 120 180 minutes

(p.o.)

Percentage

-28.2 -26.6 -27.3 -27.8 -22.8

of inhibi-

tion

______________________________________

›EXAMPLE 20

2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1,2,3,4-tetrahydro-2-isoquinolinyl)propyl]mercaptoacetonitrile hydrochloride hydrate

The process described in Example 15 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(1,2,3,4-tetrahydro-2-isoquinolinyl)-2-propanol as starting materials to yield 3.1 g of named product, m.p.: 140° C. (from ethanol).

______________________________________

Analysis for C.sub.22 H.sub.30 ClN.sub.3 O.sub.3 S.H.sub.2 O (molecular

weight 506.05)

C H N Cl

______________________________________

calculated: 59.33 6.37 8.30 7.01%;

found: 59.29 6.38 7.96 7.03%.

______________________________________

›EXAMPLE 21

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]mercaptoacetonitrile hydrochloride

The process described in Example 1 is followed by using 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(4-methyl-1-piperazinyl)-2-propanol as starting materials to give the named product in a yield of 1.7 g, m.p.: 243° C. (from 90% ethanol).

______________________________________

Analysis for C.sub.21 H.sub.32 Cl.sub.2 N.sub.4 O.sub.3 S (molecular

weight 491.48)

›C H N S

______________________________________

calculated: 51.32 6.56 11.40

6.52%;

found: 51.35 6.61 11.24

6.57%.

______________________________________

›EXAMPLE 22

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-methyl-piperazinyl)propyl]mercaptoacetonitrile hydrochloride

The process described in Example 1 is followed by using 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1-chloro-3-(4-methyl-1-piperazinyl)-2-propanol as starting substances to yield 1.8 g of the named hydrochloride, which crystallizes with 2.5 moles of crystal water from 96% ethanol, m.p.: 220° C.

______________________________________

Analysis for C.sub.23 H.sub.36 Cl.sub.2 N.sub.4 O.sub.3 S.2.5H.sub.2 O

(molecular weight 564.57)

›C H N S

______________________________________

calculated: 48.93 7.32 9.92 5.68%;

found: 48.96 7.05 10.15

6.05%.

______________________________________

›Examples3

›EXAMPLE 23

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-acetoxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile hydrochloride

After adding 80 ml of benzene and 32 ml of acetic acid anhydride to 4.8 g of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile, the reaction mixture is refluxed for 2 hours, then evaporated to dryness under reduced pressure. The residue is dissolved in isopropanol and acidified by adding abs. ethanolic hydrogen chloride solution to give the title hydrochloride in a yield of 4.72 g, m.p.: 204° C. (from abs. ethanol).

______________________________________

Analysis for C.sub.22 H.sub.30 ClN.sub.3 O.sub.5 S (molecular weight

484.01)

C H N Cl S

______________________________________

calculated:

54.59 6.25 8.68 7.33 6.63%;

found: 54.37 6.16 8.90 7.41 6.39%.

______________________________________

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-33.8 -30.9 -29.5

protective effect

______________________________________

›EXAMPLE 24

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-acetoxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile

After adding 50 ml of benzene and 20 ml of acetic acid anhydride to 3.0 g of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile, the reaction mixture is refluxed for 1 hour, then evaporated to dryness under reduced pressure. After addition of ether, the residue crystallizes out to give the named product in a yield of 2.47 g, m.p.: 133° C. (from isopropanol).

______________________________________

Analysis for C.sub.24 H.sub.33 N.sub.3 O.sub.5 (molecular weight

______________________________________

475.59)

calculated: N 8.84; S 6.74%;

found: N 8.71; S 6.66%.

______________________________________

Inhibition of the constrictive action of acetylcholine pd' 2 : 5.02

Inhibition of the constrictive action of serotonin pd' 2 : 5.05

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-25.8 -20.3 -20.0

protective effect

______________________________________

›EXAMPLE 25

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-benzoyloxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile

After adding 40 ml of benzene, 1.0 g of triethylamine and 1.5 g of benzoyl chloride to 4.06 g of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile, the reaction mixture is refluxed for 45 minutes, then cooled down and filtered. After evaporating the filtrate, the residue crystallizes out on adding ethyl acetate to obtain the named product in a yield of 3.25 g, m.p.: 144° C. (from isopropanol).

______________________________________

Analysis for C.sub.27 H.sub.31 N.sub.3 O.sub.5 S (molecular weight

509.61)

›C H N S

______________________________________

calculated: 63.63 6.13 8.25 6.29%;

found: 64.03 6.37 8.58 6.37%.

______________________________________

Inhibition of the constrictive action of acetylcholine pd' 2 : 4.81

Results of the carrageenin-induced rat paw edema test

______________________________________

50 mg/kg (p.o.)

1.5 3 4.5 hours

Percentage of the

-26.6 -17.7 -16.0

protective effect

______________________________________

›Examples7

›EXAMPLE 26

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-benzoyloxy-3-(4-morpholinyl)-propyl]mercaptoacetonitrile hydrochloride

40 ml of benzene, 1.0 g of triethylamine and 1.5 g of benzoyl chloride are added to 4.34 g of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile and the reaction mixture is refluxed for 45 minutes, then cooled down. After filtering and evaporating the solvent under reduced pressure, the residue is dissolved in isopropanol and acidified by adding abs. ethanolic hydrogen chloride solution. In this way 3.77 g of the named hydrochloride crystallize out, m.p.: 207° C. (from ethanol).

______________________________________

Analysis for C.sub.29 H.sub.36 ClN.sub.3 O.sub.5 S (molecular weight

574.13)

C H N Cl S

______________________________________

calculated:

60.66 6.32 7.32 6.18 5.59%;

found: 60.80 6.37 7.22 6.24 5.88%.

______________________________________

Inhibition of the constrictive action of acetylcholine pd' 2 : 4.81.

›EXAMPLE 27

Preparation of (-)-2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile d-camphorsulfonate

The mixture containing 8.0 g of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile and 3.9 g of d-camphorsulfonic acid in 50 ml of abs. ethanol is heated until dissolution of the solid material (a few minutes). After cooling down the crystalline precipitate is filtered and recrystallized from 40 ml of hot abs. ethanol to give 5.0 g of the named salt, m.p.: 172° C.

The base is liberated by adding sodium hydroxide to an aqueous solution of the camphorsulfonate salt. The base melts at 97° C., [α]=-11.3° (c=1, chloroform).

The hydrochloride of the product can be precipitated from anhydrous ethanolic solution by adding anhydrous ethanolic hydrogen chloride solution.

›EXAMPLE 28

a) Preparation of (+)-2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile hydrochloride

The ethanolic mother liquor of the salt separation described in Example 27 is evaporated to dryness under reduced pressure and water is added to the residue. After alkalizing the solution obtained by 10% sodium hydroxide solution, the separated oily yellow material is extracted into chloroform. After drying the chloroform solution over anhydrous sodium sulfate and evaporating the solvent under reduced pressure, the residue is dissolved in abs. ethanol and acidified by adding ethanolic hydrogen chloride solution. The named hydrochloride is obtained in a yield of 2.65 g, m.p.: 201° C. (from abs. ethanol), [α]=7.7° (c=1, water).

b) Preparation of (+)-2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile 1-camphorsulfonate

The process descried in Example 27 is followed by using 8.0 g of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile and 3.9 g of 1-camphorsulfonic acid as starting substances to obtain 5.2 g of the named camphorsulfonate salt, m.p.: 169°-170° C. (from abs. ethanol).

›EXAMPLE 29

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile hydrochloride

After adding 4 ml of 10% sodium hydroxide solution and 6 ml of ethanol to 0.48 g of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-acetoxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile hydrochloride (product of Example 23), the reaction mixture is refluxed for 30 minutes, then ethanol is evaporated under reduced pressure. The oily residue crystallizes out, it is filtered, washed with water and dried. The product obtained is dissolved in 5 ml of abs. ethanol under heating and the solution is acidified by abs. ethanolic hydrogen chloride solution to give 0.4 g of the named hydrochloride which is identical to the product of Example 17, m.p.: 210° C.

›EXAMPLE 30

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile hydrochloride

After adding 4 ml of 10% sodium hydroxide solution and 6 ml of ethanol to 0.48 g of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-acetoxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile (product of Example 24), the reaction mixture is refluxed for 30 minutes. After evaporation of the solvent, the residue is extracted with chloroform. The organic solution is dried over anhydrous sodium sulfate. After evaporating the solvent, the residue is dissolved in 5 ml of anhydrous ethanol under heating and acidified by abs. ethanolic hydrogen chloride solution to obtain 0.38 g of the named hydrochloride, which is identical to the product of Example 18, m.p.: 203° C.

›EXAMPLE 31

Preparation of 2-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-[2-hydroxy-3-(1-piperidinyl)propyl]mercaptoacetonitrile hydrochloride

After dissolving 3.85 g of S-[α-cyano-α-(6,7-dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide in the mixture of 80 ml of methanol and 20 ml of water, 11.0 ml of 10% sodium hydroxide solution are added, the reaction mixture is refluxed for 2 hours and a solution containing 1.44 g of 1,2-epoxy-3-(1-piperidinyl)propane [prepared as described in J. Am. Chem. Soc. 80, 1257 (1958)] dissolved in 5 ml of methanol is added dropwise to the hot solution. The reaction mixture is refluxed for additional 5 hours. After evaporating methanol under reduced pressure the reaction mixture is worked up as described in Example 1 to obtain 2.3 g of the named hydrochloride which is identical to the product of Example 15, m.p.: 210° C. (from anhydrous ethanol).

›EXAMPLE 32

Preparation of 2-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-piperidinyl)propyl]mercaptoacetonitrile hydrochloride

The process described in Example 31 is followed by using 4.15 g of S-[α-cyano-α-(6,7-diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)methyl]isothiuronium bromide and 1.41 g of 1,2-epoxy-3-(1-piperidinyl)propane to give 2.6 g of the named hydrochloride, m.p.: 92° C.

Claims

33 · 2 independent · depth 2

33 granted claims

›1.independentRacemic or optically active isoquinoline derivatives of the formula (I), ##STR13## wherein R means hydrogen or a straight or branched chain C.sub.1-6 …+31

›2.↳ 1Racemic or optically active compounds as claimed in claim 1, wherein R stands for a methoxy or ethoxy group, R.sup.1 and R.sup.2 are hydrogen, R.sup.3…d2

›3.↳ 1Racemic or optically active compounds as claimed in claim 1, wherein ##STR16## represents a pyrrolidinyl, piperidinyl, morpholinyl or hexamethylenimin…d2

›4.↳ 12-(6 ,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-diethylamino-2-h ydroxypropyl)-mercaptoacetonitrile or the hydrochloride thereof defin…d2

›5.↳ 12-(6,7 -Diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-diethylamino-2-hydr oxypropyl)-mercaptoacetonitrile or the hydrochloride thereof define…d2

›6.↳ 12-(6,7 -Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[3-(N-methyl-N-2-hydr oxyethyl)amino-2-hydroxypropyl]mercaptoacetonitrile or the hydrochl…d2

›7.↳ 12-(6,7-Dimethoxy-1,2,3,4- tetrahydro-1-isoquinolinylidene)-2-[3-(N,N-bis-2-hydroxyethyl)amino-2-hydro xypropyl]mercaptoacetonitrile or the hydrochlori…d2

›8.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1 -isoquinolinylidene)-2-[3-(N,N-bis-2-hydroxyethyl)amino-2-hydroxypropyl]me rcaptoacetonitrile or the hydrochlorid…d2

›9.↳ 12-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(2-h ydroxy-3-isopropylaminopropyl)mercaptoacetonitrile or the hydrochloride thereof or th…d2

›10.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(2-hydroxy-3 -isopropylaminopropyl)mercaptoacetonitrile or the hydrochloride thereof define…d2

›11.↳ 12-(6,7-Dimethoxy -1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-tert-butylamino-2-hydroxypro pyl)mercaptoacetonitrile or the hydrochloride thereof def…d2

›12.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-(3-tert-buty lamino-2-hydroxypropyl)mercaptoacetonitrile or the hydrochloride thereof or th…d2

›13.↳ 12-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene) -2-(3-cyclohexylamino-2-hydroxypropyl)mercaptoacetonitrile or the hydrochloride thereof defi…d2

›14.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-i soquinolinylidene)-2-(3-cyclohexylamino-2-hydroxypropyl)mercaptoacetonitril e or the hydrochloride thereof defi…d2

›15.↳ 12-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquino linylidene)-2-[2-hydroxy-3-(1-pyrrolidinyl)propyl]mercaptoacetonitrile or the hydrochloride thereof or …d2

›16.↳ 12-(6,7-Diethoxy- 1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-pyrrolidinyl)pro pyl]mercaptoacetonitrile or the hydrochloride thereof def…d2

›17.↳ 12-(1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-piperidin yl)propyl]mercaptoacetonitrile or the hydrochloride thereof defined in claim 1…d2

›18.↳ 12-(6, 7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1-pipe ridinyl)propyl]mercaptoacetonitrile or the hydrochloride thereof def…d2

›19.↳ 12-(1, 2,3,4-Tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl ]mercaptoacetonitrile or hydrochloride thereof or hemihydrate of the…d2

›20.↳ 12-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1- isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitri le or the hydrochloride thereof def…d2

›21.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-isoquinoli nylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile or the hydrochloride thereof defin…d2

›22.↳ 12-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1- isoquinolinylidene)-2-(3-hexamethylenimino-2-hydroxypropyl)mercaptoacetonit rile or hydrochloride thereof or he…d2

›23.↳ 12-(6,7-Dimethoxy -1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(1,2,3,4-tetrahydr o-2-isoquinolinyl)propyl]mercaptoacetonitrile or hydrochl…d2

›24.↳ 12-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene) -2-[2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]mercaptoacetonitrile or the hydrochloride the…d2

›25.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-i soquinolinylidene)-2-[2-hydroxy-3-(4-methyl-1-piperazinyl)propyl]mercaptoac etonitrile or the hydrochloride the…d2

›26.↳ 12-(6,7-Dimethoxy-1,2,3,4-te trahydro-1-isoquinolinylidene)-2-[2-acetoxy-3-(4-morpholi mercaptoacetonitrile or the hydrochloride thereof defined in cla…d2

›27.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-acet oxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile as defined in claim 1.d2

›28.↳ 12-(6,7-Dimethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-benzoylo xy-3-(4-morpholinyl)propyl]mercaptoacetonitrile as defined in claim 1.d2

›29.↳ 12-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylidene)-2-[2-benz oyloxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile or the hydrochloride thereof de…d2

›30.↳ 1(-)-2-(6,7-Diethoxy-1,2, 3,4-tetrahydro-1-isoquinolinylidene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]m ercaptoacetonitrile (+)-camphorsulfonate defined …d2

›31.↳ 1(+)-2-(6,7-Diethoxy-1,2,3,4-tetrahydro-1-isoquinolinylid ene)-2-[2-hydroxy-3-(4-morpholinyl)propyl]mercaptoacetonitrile or the hydrochloride thereof d…d2

›33.↳ 1A method of treating asthma which comprises the step of administering to an affected patient an effective amount of a compound defined in claim 1.d2

›32.independentA pharmaceutical composition, which comprises as active ingredient a racemic or optically active isoquinoline derivative of the formula (I), ##STR17##…

Classifications

18 codes

IPC · International Patent Classification

Section A — Human necessities

A61P37/08
A61K31/472
A61P29/00
A61K31/4725
A61P11/08
A61K31/33
A61K31/47

Section C — Chemistry; metallurgy

C07D217/12
C07D217/26
C07D217/16

USPC · US Patent Classification

514/212540/597544/128544/363546/145514/307514/235.2514/253

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

1.2 y

425 days filing → grant

Office actions

on the grant's record

Examiner

Robert W. Ramsuer

art unit 121 · TC 1200

Law firm

Law firm · Log in to unlock

Citations: 2 back · 2 forward

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Worldwide family

43 members · 27 offices

this patentIP5 & PCTother officessolid = grantedhover for detail · click to open

Members

DOCDB simple family 10972178

Offices

US · EP · JP · KR · CN

Granted

8 of 43

grant date present

Non-English titles

shown as filed, never translated

›IP5 & PCT — 7 members

Office	Publication	Kind	Published	Filed	Status	Title
USthis patent	US-5179089-A	A	12 Jan 1993	14 Nov 1991	granted	Isoquinoline compounds, compositions and use
EP	EP-0486211-A1	A1	20 May 1992	6 Nov 1991	published	Dérivés d'Isoquinoléinefr
JP	JP-H04283567-A	A	8 Oct 1992	14 Nov 1991	published	Novel compound, medicinal composition containing the novel compound and process for producing same
JP	JP-H0772178-B2	B2	2 Aug 1995	14 Nov 1991	published	新規化合物、新規化合物含有医薬組成物及びその製造方法ja
KR	KR-920009801-A	A	25 Jun 1992	14 Nov 1991	published	신규한 이소퀴놀린 화합물(들)과 이들을 함유하는 약제학적 조성물 및 그들의 제조방법ko
KR	KR-950011412-B1	B1	4 Oct 1995	14 Nov 1991	granted	Novel isoquinoline compounds pharmaceutical compositions containing them and process for preparing same
CN	CN-1061409-A	A	27 May 1992	14 Nov 1991	published	New compound, contain drug regimen of these new compounds and preparation method thereof

›Other offices — 36 members

Office	Publication	Kind	Published	Filed	Status	Title
AR	AR-248272-A1	A1	12 Jul 1995	13 Nov 1991	granted	Isoquinoline derivatives
AU	AU-8777391-A	A	21 May 1992	13 Nov 1991	published	Novel compounds, pharmaceutical compositions containing them and process for preparing same
AU	AU-637010-B2	B2	13 May 1993	13 Nov 1991	granted	Novel compounds, pharmaceutical compositions containing them and process for preparing same
BG	BG-95460-A	A	24 Dec 1993	13 Nov 1991	published	Изохинолинови производниbg
BG	BG-60584-B1	B1	29 Sep 1995	13 Nov 1991	published	Isoquinoline derivatives
CA	CA-2055225-A1	A1	15 May 1992	8 Nov 1991	published	Composes, compositions pharmaceutiques les renfermant et procede pour les preparerfr
CS	CS-344191-A3	A3	17 Jun 1992	13 Nov 1991	published	Novel isoquinoline derivatives, process of their preparation and pharmaceuticals comprising them
CZ	CZ-280715-B6	B6	17 Apr 1996	13 Nov 1991	published	Novel isoquinoline derivatives, process of their preparation and pharmaceuticals comprising them
EE	EE-02961-B1	B1	17 Feb 1997	26 Aug 1994	published	Isokinoliini derivaadid, neid sisaldavad ravimvormid ja nende saamise protsesset
FI	FI-915354-A0	A0	13 Nov 1991	13 Nov 1991	published	Förfarande för framställning av nya terapeutiskt användbara isokinolinderivatsv
FI	FI-915354-A7	A7	15 May 1992	13 Nov 1991	published	Menetelmä uusien terapeuttisesti käyttökelpoisten isokinoliinijohdannaisten valmistamiseksifi
FI	FI-96417-B	B	15 Mar 1996	13 Nov 1991	granted	Förfarande för framställning av nya terapeutiskt användbara isokinolinderivatsv
FI	FI-96417-C	C	25 Jun 1996	13 Nov 1991	granted	Förfarande för framställning av nya terapeutiskt användbara isokinolinderivatsv
HU	HU-907125-D0	D0	28 May 1991	14 Nov 1990	published	Ophtalmological examinational process and apparatus for detecting and registration of dimnesses in refracting media of human eye mainly in lens
HU	HU-T62271-A	A	28 Apr 1993	14 Nov 1990	published	Process for producing 2-mercapto-2-(1-isoquinilidilene)-acetonitrile derivatives and pharmaceutical compositions comprising same
HU	HU-209930-B	B	28 Dec 1994	14 Nov 1990	published	Process for producing of 2-mercapto-2-(1-isoquinolylidene)-acetonitrile derivatives and pharmaceutical compositions comprising them
IE	IE-913777-A1	A1	20 May 1992	29 Oct 1991	published	Novel compounds, pharmaceutical compositions containing them¹and process for preparing same
IL	IL-99900-A0	A0	18 Aug 1992	30 Oct 1991	published	Quinoline derivatives,pharmaceutical compositions containing them and process for preparing same
IL	IL-99900-A	A	31 Jul 1995	30 Oct 1991	published	Isoquinoline derivatives, pharmaceutical compositions containing them and process for preparing same
MY	MY-107827-A	A	29 Jun 1996	14 Nov 1991	published	Isoquinolline compounds, compositions and use
NO	NO-914452-D0	D0	13 Nov 1991	13 Nov 1991	published	Fremgangsmaate for fremstilling av isokinolinderivaterno
NO	NO-914452-L	L	15 May 1992	13 Nov 1991	published	Fremgangsmaate for fremstilling av isokinolinderivaterno
NO	NO-179041-B	B	15 Apr 1996	13 Nov 1991	published	Analogifremgangsmåte for fremstilling av terapeutisk aktive, racemiske eller optisk aktive isokinolinderivaterno
NO	NO-179041-C	C	24 Jul 1996	13 Nov 1991	published	Analogifremgangsmåte for fremstilling av terapeutisk aktive, racemiske eller optisk aktive isokinolinderivaterno
NZ	NZ-240581-A	A	26 May 1994	13 Nov 1991	published	1,2,3,4-tetrahydroisoquinolinylidine derivatives and pharmaceutical compositions
PL	PL-292371-A1	A1	2 Nov 1992	13 Nov 1991	published	Method of obtaining novel isoquinoline derivatives
PL	PL-166695-B1	B1	30 Jun 1995	13 Nov 1991	published	Sposób wytwarzania nowych pochodnych izochinoliny PL PL PLpl
PT	PT-99485-A	A	30 Sep 1992	12 Nov 1991	published	Processo para a preparacao de novos derivados de isoquinolina e de preparacoes farmaceuticas que os contempt
PT	PT-99485-B	B	30 Apr 1999	12 Nov 1991	published	Processo para a preparacao de novos derivados de isoquinolina e de preparacoes farmaceuticas que os contempt
RO	RO-112614-B1	B1	28 Nov 1997	12 Nov 1991	published	Derivati de izochinolina, procedeu de preparare si compozitie farmaceutica care ii continero
RU	RU-2090559-C1	C1	20 Sep 1997	13 Nov 1991	granted	Рацемические или оптически активные производные изохинолина, способ их получения, фармацевтическая композиция на их основе и способ получения фармацевтической композицииru
SK	SK-278791-B6	B6	4 Mar 1998	13 Nov 1991	published	Izochinolínové deriváty, spôsob ich výroby a farmask
TW	TW-202435-B	B	21 Mar 1993	5 Dec 1991	granted	no title held
YU	YU-179991-A	A	10 Jun 1994	14 Nov 1991	published	Racemski ili optički izohinolinski derivatish
YU	YU-48255-B	B	30 Sep 1997	14 Nov 1991	published	Racemski ili optički aktivni izohinolin derivati, postupak za njihovo dobivanje i postupak za dobivanje farmaceutskih preparata koji ih sadržesh
ZA	ZA-918644-B	B	28 Oct 1992	30 Oct 1991	published	Novel compounds,pharmaceutical compositions containing them and process for preparing same

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.